epcoritamab是一种在研的IgG1双特异性抗体，可同时结合T细胞上的CD3和恶性B细胞上的cd20。 epcoritamab是一种在研的IgG1双特异性抗体，可同时结合T细胞上 ...

Prior to the AbbVie announcement, epcoritamab (GEN3013 ... The trial showed that the double-headed antibody – which targets CD3 on white blood cells and CD20 on tumour cells – was tolerable ...

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non ...